The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
A case study will be presented focusing an autologous T Cell product in late stage development. To maximize patient access to safe and effective quality product, the variance that is contributed by patient heterogeneity and product knowledge of the quality attribute-clinical outcome relationship must be considered to establish a patient-centric specification
Speaker(s):
Kenneth
Riker,
Juno Therapeutics, A Bristol-Myers Squibb Company
You must be logged in and own this session in order to
post comments.